Antimalarials: An update in rheumatic diseases;Antipalúdicos: Actualización de su uso en enfermedades reumáticas

Reumatologia Clinica

Volumn 2, Issue 4, 2006, Pages 190-201

  Jiménez Palop, Mercedes ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Antimalarials; Chloroquine; Hydroxychloroquine; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLIN DERIVATIVE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BLOOD DYSCRASIA; CLINICAL TRIAL; CONVULSION; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; EYE TOXICITY; GASTROINTESTINAL TOXICITY; HEART FAILURE; HUMAN; HYPOGLYCEMIA; HYPOLIPEMIA; IMMUNOMODULATION; INSOMNIA; KIDNEY DYSFUNCTION; MACULOPAPULAR RASH; MENTAL DISEASE; MYASTHENIA; NAUSEA AND VOMITING; NEUROPATHY; NONHUMAN; PIGMENT DISORDER; PRURITUS; RASH; RESTRICTIVE CARDIOMYOPATHY; RETINOPATHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SKIN PROTECTION; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TINNITUS; URTICARIA; VERTIGO;

EID: 33748747311     PISSN: 1699258X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1699-258X(06)73045-5     Document Type: Review

References (126)

1. Page F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951;2:755-8.
2. Wallace DJ. The History of antimalarial. Lupus. 1996;5 Suppl 1:S2-3.
3. Wallace DJ. Is there a role for quinacrina (Atabrine) in the new millennium? Lupus. 2000;9:81-2.
4. Toubi E, Rosner I, Rozenbaum M, Kessel A, Golan TD. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus. 2000;9:92-5.
5. Scherbel AL, Harrison JW, Atdjan M. Further observations on the use of 4-aminoquinoline compounds in patients with rheumatoid arthritis related diseases. Cleve Clin Q. 1958;25:95.
6. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996;5 Suppl 1:S11-5.
7. Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1460-9.
8. Landewe RB, Vergouwen MS, Goeei The SG, Van Rijthoven AW, Breedveld FC, Dijkmans BA. Antimalarial drug induced decrease in creatinine clearance. J Rheumatol. 1995;22:34-7.
9. Rubin M, Bernstein HN, Zvaifler NJ. Studies on the pharmacology of chloroquine. Arch Ophthalmol. 1962;70:474.
10. Aponte J, Petrelli M, Von Dawson N. Liver enzyme levels in artritis patirnts treated with long-term bolus methotrexate. Arthritis Rheum. 1992;35:126-8.
11. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000;42:983-7.
12. Pool B, Ohkuma S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol. 1981;90:665-9.
13. Fox RI. Mechanism of action of hydroxycloroquine as an antirheumatic drug. Sem Arthritis Rheum. 1993;23:82-91.
14. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drugs development. Lupus. 1996;5 Suppl 1:S4-10.
15. Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Brit J Rheumatol. 1997;36:799-805.
16. Bondeson J, Sundler R. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1β and tumor necrosis factor α in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmac. 1998;30:357-66.
17. Murphy GM, Hawk JLM, Magnus IA. Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. Brit J Dermatol. 1987;116:379-86.
18. Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus. 2000; 11;71-81.
19. Nguyen TQ, Capra JD, Sontheimer RD. 4-aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation. Lupus. 1998; 7:148-53.
20. Lafont H, Chanussor F, Dupuy C, Lechene P, Lairon D, Charbonnier-Augeire M, et al. Influence of acute injection of chloroquine on the biliary secretion of lipids and lysosomal enzyme on rats. Lipids. 1984; 19:195-201.
21. Goldstein JL, Brunschede GY, Brown MS. Inhibition of ptoteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A and Triton WR 1339. J Biol Chem. 1975;250:7854-62.
22. Chen HW, Leonard DA. Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalians cells. J Biol Chem. 1984;259:8156-62.
23. Beynen AC, Van der Moolen AJ, Geelen MJH. Inhibition of hepatic colesterol síntesis by chloroquine. Lipids. 1981;16:472-4.
24. Svenson KLG, Lithell H, Hällgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med. 1987;147:1917-20.
25. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med. 1990;89:322-6.
26. Tam LS, Li EK, Lam CW, Tomlinson B. Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus. 2000;9:413-6.
27. Hodis HN, Quismorio FP, Wickham E, Blankenhorn DH. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol. 1993;20:661-5.
28. Petri M, Lakata C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data análisis. Am J Med. 1994;96:254-9.
29. Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol. 1997;3:3-8.
30. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis. 1997;56:374-7.
31. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol. 1999;26: 325-30.
32. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol. 2000;27:2142-5.
33. Borba EF, Bonfá E. Longterm beneficial effect of choloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol. 2001;28:780-5.
34. Phillips RE, Looareesuwan S, White NJ, Chanthavanich P, Karbwang J, Supanaranond W, et al. Hypoglycemia and antimalarial drugs: quinidine and release of insulin. BMJ. 1986;292:1319-21.
35. Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A, et al. Hydroxychloroquine in decompensated treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med. 1990;112:678-81.
36. Petri M. Hydroxychloroquine use in the Baltimore lupus cohort: efects on lipids, glucose and thrombosis. Lupus. 1996;5 Suppl 1:S16-22.
37. Shojania K, Koehler BE, Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol. 1999;26:195-6.
38. Loudon JR. Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Am J Med. 1988;85 Suppl 44:57-61.
39. Carter AE, Eban R, Perrett RD. Prevention of post-operative deep venous thrombosis and pulmonary embolism. BMJ. 1971;1:312-4.
40. Carter AE, Eban R. Prevention of postoperative deep venous trombosis in legs by orally administered hydroxychloroquine sulfate. BMJ. 1974; 3:94-5.
41. Pilcher DB. Hydroxychloroquine sulfate in prevention of thromboembolic phenomena in surgical patients. Am Surgeon. 1975;41:761-6.
42. Hansen EH, Jessing P, Lindewald H, Ostergaard P, Olesen T, Malver EI. Hydroxychloroquine sulphate in prevention of deep venous thrombosis following of the hip, pelvis, or thoracolumbar spine. J Bone Joint Surg Am. 1976;58:1089-93.
43. Chrisman DO, Snook GA, Wilson TC, Short JY. Prevention of venous thromboembolism by administration of hydroxychloroquine. J Bone Joint Surg Am. 1976;58:918-20.
44. Cook ED, Dawson MH, Ibbotson RM, Bowcock SA, Ainsworth ME, Pilcher MF. Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. J Bone Joint Surg Am. 1977;59:496-500.
45. Wu TK, Tsapogas MJ, Jordan FR. Prophylaxis of deep venous trombosis by hydroxychloroquine sulfate and heparin. Surg Gynecol Obstet. 1977; 145:714-8.
46. Johnnsson E, Forsberg K, Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis. 1981;10:89-96.
47. Bertrand E, Cloitre B, Ticolat R, Bile RK, Gautier C, Abiyou GO, et al. Antiaggregation action of cholroquine. Med Trop. 1990;50:143-6.
48. Nosal R, Jancinova V, Petrikova M. Chloroquine inhibits atimulated platelets at the arachidonic acid pathway. Thromb Res. 1995;77:531-42.
49. Madow BP. Use of antimalarial drugs as "desludging" agents in vascular disease processes. JAMA. 1960;172:1630-3.
50. Edwards MH, Pierangeli S, Liu XW, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96:4380-4.
51. Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 1987;30:1435-6.
52. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial theraphy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus. 1993;2 Suppl 1:S13-5.
53. Petri M, Hochberg, Hellmann D, Goldman D. Incidence and predictors of thrombotic events in SLE: protective role of hydroxychloroquine. Arthritis Rheum. 1992;35 Suppl 9:S54.
54. McCarthy GA. Hydroxychloroquine (HCQ) treatment in antiphospholipid antibody syndrome (APS): time course of clinical improvement and antiphospholipid antibody (aPL) titer changes over 4 years. Arthritis Rheum. 2000;43 Suppl 9:S1061.
55. Khamashta MA, Wallace DJ, editors. Antimalarial in rheumatology. Lupus. 1996;5 Suppl 1:S1-73.
56. Yoon KH. Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in Antiphospholipid Antibody (Hughes') Syndrome. J Rheumatol. 2002;29:1574.
57. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin N Am. 1994;20:243-63.
58. Christiansen JV, Nielsen JP. Treatment of lupus erytematosus with mepacrine: results and relapses during a long observation. Brit J Dermatol. 1956;68:73-87.
59. Ziff M, Esserman P, McEwen C. Observations on the course and treatment of systemic lupus erythematosus. Arthritis Rheum. 1958;1:332-50.
60. Dubois EL, Martel S. Discoid lupus erythematosus; an analysis of its systemic manifestations. Ann Intern Med. 1956;44:482-96.
61. Rudnicki RD, Gresham GE, Rothfield NF. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol. 1975;2:323-30.
62. The Canadian Hydroxychloroquine Study Group. A randomized study of of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. New Engl J Med. 1991;324:150-4.
63. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus. 1998;7:80-5.
64. Williams HJ, Egger MJ, Singer JZ, Willkens RF, Kalunian KC, Clegg DO, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythrmatosus. J Rheumatol. 1994;21:1457-62.
65. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus. 1996;5:237-41.
66. Morand EF, McCloud PI, Littlejohn GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 1992;51:1318-21.
67. Petri M. Hydroxychloroquine: past, present, future. Lupus. 1998;7:65-7.
68. Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of Israeli cohort. Lupus. 2002; 11:356-61.
69. Fessler BJ, Alarcón GS, McGwin G, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52:1473-80.
70. Jessop S, Whitelaw D, Jordaan F. Drugs for lupus erythematosus (Cochrane Review). En: The Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons, Ltd.; 2004.
71. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med. 2003;349:2379-80.
72. Davis MJ, Woolf AD. Role of antimalarial in rheumatoid arthritis -the Brithish experience. Lupus. 1996;5 Suppl 1:S37-40.
73. Khraishi MM, Singh G. The role of anti-malarial in rheumatoid arthritis - the American experience. Lupus. 1996;5 Suppl 1:S41-4.
74. Suárez-Almanzor MB, Belseck E, Shea B, Holmik J, Wells G, Tugwell P. Drogas antipalúdicas para la artritis reumatoidea. En: La Cochrane Library plus en español. Oxford: Update Software; 2000.
75. Blackburn WD, Prupas HM, Silverfield JC, Poiley JE, Caldwell JR, Collins RL, et al. Tenidap in rheumatoid arthritis. A 24-week double-bind comparison with hydroxychloroquine-plus-piroxicam and piroxicam alone. Arthritis Rheum. 1995;38:1447-56.
76. Clark P, Casas E, Tugwell P, Medina C, Gheno C, Tenorio G, et al. Hydroxychloroquine compared with placebo in rheumatoid artritis. A randomized controlled trial. Ann Intern Med. 1993;119:1067-71.
77. Davis MJ, Dawes PT, Fowler PD, Clarke S, Fisher J, Shadforth MF. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol. 1991;30:451-4.
78. Esdaile JM, Suissa S, Shiroky JB, Lamping D, Tsakonas E, Anderson D, et al. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am J Med. 1995;98:156-68.
79. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a meta-analysis of published clinicals trials. Arthritis Rheum. 1992;35:1117-25.
80. Csuka M, Carrera GF, McCarty DJ. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study. JAMA. 1986;255:2315-9.
81. Tialakos NA. Low-dose cytotoxic drug combianation therapy in intractable rheumatoid artritis: two years later. Arthritis Rheum. 1986;29:S79.
82. McCarty DJ, Harman JG, Grassanovich JL, Oian C, Klein JP. Combination drug therapy of seropositive rheumatoid arthritis. J Rheumatol. 1995;22:1636-45.
83. Wilke WS, Clough JD. Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment. Semin Arthritis Rheum. 1991;21:21-34.
84. Langevitz P, Kaplinsky N, Ehrenfeld M, Pras M. Intractable RA - treatment with combined methotrexate, azathioprine and hydroxychloroquine. Br J Rheumatol. 1989;28:271-2.
85. Scott DL, Dawes PT, Tunn E, Fowler PD, Shandforth MF, Fisher J, et al. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study. Br J Rheumatol. 1989;28:128-33.
86. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis-no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol. 1993; 20:645-9.
87. Martin M. A combination of D-penicillamine and hydroxychloroquine for the treatment of rheumatoid arthritis. Ann Rheum Dis. 1982;41:208.
88. Bunch TW, O'Duffy JD, Tompkin RB, O'Fallon WM. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum. 1984;27: 267-76.
89. Gibson T, Emery P, Armstrong RD, Crisp AJ, Panayi GS. Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis - a comparative study. Br J Rheumatol. 1987;26:279-84.
90. Faarvang KL, Egsmose C, Kryger P, Podenphant J, Ingeman-Nielsen M, Hansen TM. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. Ann Rheum Dis. 1993;52:711-5.
91. Fries JF, Singh G, Lenert L, Furst DE. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum. 1990;33:1611-9.
92. Seideman P, Albertioni F, Beck O, Eksborg S, Peterson C. Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity. Arthritis Rheum. 1994;37:830-3.
93. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckiioff S, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334:1287-91.
94. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353:1568-73.
95. Calguneri M, Pay S, Caliskaner Z, Apras S, Kiraz, Ertenli I. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol. 1999;17:699-704.
96. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum. 2004;50:55-62.
97. Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus. 1996;5 Suppl 1:S59-64.
98. Fox RI, Chan E, Benton L, Friedlaender M, Howell FV. Treatment of primary Sjogren's syndrome with hydroxychloroquine. Am J Med. 1988; 85:62-7.
99. Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996;5 Suppl 1:S31-6.
100. Kruize AA, Hene RJ, Kallenberg CG, Bijsterveld OP, Van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993; 52:360-4.
101. González-López L, Gámez-Nava JI, Jhangri G, Russell AS, Suárez-Almazor ME. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J Rheumatol. 2000; 27:41-6.
102. Youssef W, Yan A, Russell AS. Palindromic rheumatism: a response to chloroquine. J Rheumtol. 1999;18:35-7.
103. Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. J Rheumatol. 1992;19:1724-6.
104. Athreya BH, Cassidy JT. Current status of the medical treatment of children with juvenile rheumatoid arthritis. Rheum Dis Clin North Am. 1991;17:871-89.
105. Bryant LR, Des Rosier KF, Carpenter MT. Hydroxychloroquine in the treatment of erosive osteoarthritis. J Rheumatol. 1995;22:1527-31.
106. Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997;23:327-31.
107. Ullberg S, Lindquist NG, Sjostrand SE. Accumulation of chorio-retinotoxic drugs in the foetal eye. Nature. 1970;227:1257-8.
108. Hart CN, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg. 1964;80:407-12.
109. Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Safety. 1996;14:131-45.
110. Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis. 1996;55:486-8.
111. Parke AL, West B. Hydroxychloroquine in pregnant patients with SLE. J Rheumatol. 1996;23:1715-8.
112. Goupille P. Grossesse et polyarthrite rhumatoïde. Rev Rhum. (Suppl Pédagogique). 1997;64:174SP-82SP.
113. Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet. 2001;358:813-4.
114. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10:401-4.
115. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong Du LT, Sebbough D, Wechsler B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003;48:3207-11.
116. Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol. 2005;25:86-9.
117. Al-Herz A, Schulzer M, Esdaile JM. Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol. 2002;29:700-6.
118. Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75:25-34.
119. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2002;109:1377-82.
120. Araiza-Casillas R, Cárdenas F, Morales Y, Cardiel MH. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus. 2004;13:119-24.
121. Nord EJ, Shan PK, Rinaldi RZ, Wisman MH. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum. 2004;33:336-51.
122. Baguet J-P, Tremel F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. Heart. 1999;81:221-3.
123. Cervera A, Espinosa G, Cervera R, Font J, Ingelmo M. Cardiac toxicity secondary to long term treatment with chloroquine. Ann Rheum Dis. 2001;60:301.
124. Casado E, Larrosa M, Gratacós J, Martínez JM, Ojanguren I, Sanjuán A, et al. Antimalarial myopathy: more frecuent than we though? A longitudinal study with 119 patients. Arthritis Rheum. 2002;46:S612.
125. Avina-Zubieta JA, Johnson ES, Suárez-Almanzor ME, Russell AS. Incidence of myopathy in patients treated with antimalarials. Report of three cases and review of the literature. Br J Rheumatol. 1995;34:166-70.
126. Wallace DJ. Antimalarials-the "real" advance in lupus. Lupus. 2001;10: 385-87.